Hospital Admission and Early Management of Acute Severe Ulcerative Colitis (ASUC)
Admission Criteria
- The British Society of Gastroenterology issues a strong recommendation (100 % agreement) that any adult with ulcerative colitis who meets the modified Truelove & Witts criteria—>6 bloody stools per day plus systemic toxicity (temperature > 37.8 °C, pulse > 90 bpm, hemoglobin < 105 g/L, or CRP > 30 mg/L)—should be admitted for inpatient care. 1
Epidemiology & Expected Outcomes
- 15–25 % of all ulcerative colitis patients will experience an episode of ASUC at some stage in their disease course. 2
- In contemporary practice, the colectomy rate during the first ASUC admission ranges from 19 % to 23 %. 3
Diagnostic Evaluation on Admission
- Clostridioides difficile toxin testing is mandatory in every ASUC presentation to exclude infection‑related exacerbation. 2
- Cytomegalovirus (CMV) testing should be considered when clinically indicated (e.g., refractory disease, immunosuppression). 4
Initial Medical Therapy
- Intravenous corticosteroids are the first‑line treatment: hydrocortisone 100 mg every 6 hours or methylprednisolone 60 mg once daily. This regimen is endorsed by the British Society of Gastroenterology for all admitted ASUC patients. 1
- Pre‑biologic screening (e.g., hepatitis B/C, TB, HIV) should be performed on admission because approximately 50 % of ASUC patients fail to respond to IV corticosteroids, necessitating early rescue therapy. 3
Risk Stratification & Prognosis
- An elevated inflammatory marker profile (CRP ≈ 115 mg/L, ESR ≈ 102 mm/hr) places the patient at high risk for corticosteroid failure (≈ 50 % of ASUC cases). 1
- Such patients have a substantial likelihood of requiring rescue therapy with either biologic agents (e.g., infliximab, vedolizumab) or calcineurin inhibitors (e.g., cyclosporine). 2
- The same inflammatory burden correlates with the 19–23 % risk of needing colectomy during the index hospital stay. 3
Monitoring & Follow‑Up (post‑admission)
- Ongoing assessment should include accurate stool charting (frequency, consistency, presence of blood) and serial clinical evaluation of response to IV corticosteroids to identify early non‑responders and trigger timely escalation of therapy. 1